Healius Limited provides facilities and support services to independent general practitioners, radiologists, and other healthcare professionals in Australia.
Share Price & News
How has Healius's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: HLS is less volatile than 75% of Australian stocks over the past 3 months, typically moving +/- 4% a week.
Volatility Over Time: HLS's weekly volatility (4%) has been stable over the past year.
7 Day Return
1 Year Return
Return vs Industry: HLS exceeded the Australian Healthcare industry which returned 23.6% over the past year.
Return vs Market: HLS exceeded the Australian Market which returned 27% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is Healius's share price compared to the market and industry in the last 5 years?
Simply Wall St News
No news available
Healius Fundamentals Summary
|HLS fundamental statistics|
Is HLS overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|HLS income statement (TTM)|
|Cost of Revenue||AU$1.19b|
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
|Earnings per share (EPS)||0.11|
|Net Profit Margin||3.46%|
How did HLS perform over the long term?See historical performance and comparison
2.7%Current Dividend Yield
Is Healius undervalued compared to its fair value and its price relative to the market?
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: HLS (A$4.94) is trading above our estimate of fair value (A$4.3)
Significantly Below Fair Value: HLS is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: HLS is poor value based on its PE Ratio (44.6x) compared to the Australian Healthcare industry average (26.5x).
PE vs Market: HLS is poor value based on its PE Ratio (44.6x) compared to the Australian market (18.7x).
Price to Earnings Growth Ratio
PEG Ratio: HLS is poor value based on its PEG Ratio (5.8x)
Price to Book Ratio
PB vs Industry: HLS is good value based on its PB Ratio (1.6x) compared to the AU Healthcare industry average (2.4x).
How is Healius forecast to perform in the next 1 to 3 years based on estimates from 13 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: HLS's forecast earnings growth (7.7% per year) is above the savings rate (1.9%).
Earnings vs Market: HLS's earnings (7.7% per year) are forecast to grow slower than the Australian market (11.5% per year).
High Growth Earnings: HLS's earnings are forecast to grow, but not significantly.
Revenue vs Market: HLS's revenue is expected to decline over the next 3 years (-0.08% per year).
High Growth Revenue: HLS's revenue is forecast to decline over the next 3 years (-0.08% per year).
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: HLS's Return on Equity is forecast to be low in 3 years time (7.5%).
How has Healius performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: HLS has high quality earnings.
Growing Profit Margin: HLS's current net profit margins (3.5%) are lower than last year (5.3%).
Past Earnings Growth Analysis
Earnings Trend: HLS has become profitable over the past 5 years, growing earnings by 51.1% per year.
Accelerating Growth: HLS's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: HLS had negative earnings growth (-20.5%) over the past year, making it difficult to compare to the Healthcare industry average (61.3%).
Return on Equity
High ROE: HLS's Return on Equity (3.6%) is considered low.
How is Healius's financial position?
Financial Position Analysis
Short Term Liabilities: HLS's short term assets (A$330.9M) do not cover its short term liabilities (A$684.7M).
Long Term Liabilities: HLS's short term assets (A$330.9M) do not cover its long term liabilities (A$1.2B).
Debt to Equity History and Analysis
Debt Level: HLS's debt to equity ratio (14.2%) is considered satisfactory.
Reducing Debt: HLS's debt to equity ratio has reduced from 37.5% to 14.2% over the past 5 years.
Debt Coverage: HLS's debt is well covered by operating cash flow (198.8%).
Interest Coverage: HLS's interest payments on its debt are well covered by EBIT (4.5x coverage).
What is Healius's current dividend yield, its reliability and sustainability?
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: HLS's dividend (2.73%) is higher than the bottom 25% of dividend payers in the Australian market (2.3%).
High Dividend: HLS's dividend (2.73%) is low compared to the top 25% of dividend payers in the Australian market (5.41%).
Stability and Growth of Payments
Stable Dividend: HLS's dividend payments have been volatile in the past 10 years.
Growing Dividend: HLS's dividend payments have increased over the past 10 years.
Current Payout to Shareholders
Dividend Coverage: With its high payout ratio (123.7%), HLS's dividend payments are not well covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: HLS's dividends in 3 years are forecast to be covered by earnings (61.1% payout ratio).
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Malcolm Parmenter (66 yo)
Dr. Malcolm W. Parmenter, MB, BS, MAICD, has been the Managing Director and Chief Executive Officer at Healius Limited (formerly known as Primary Health Care Limited) since joined on September 06, 2017 & s...
CEO Compensation Analysis
Compensation vs Market: Malcolm's total compensation ($USD2.35M) is above average for companies of similar size in the Australian market ($USD1.28M).
Compensation vs Earnings: Malcolm's compensation has increased by more than 20% whilst company earnings have fallen more than 20% in the past year.
Experienced Management: HLS's management team is considered experienced (3 years average tenure).
Experienced Board: HLS's board of directors are considered experienced (3.2 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: HLS insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Healius Limited's company bio, employee growth, exchange listings and data sources
- Name: Healius Limited
- Ticker: HLS
- Exchange: ASX
- Founded: 1994
- Industry: Health Care Services
- Sector: Healthcare
- Market Cap: AU$2.954b
- Shares outstanding: 598.01m
- Website: https://www.healius.com.au
Number of Employees
- Healius Limited
- 203 Pacific Highway
- Level 6
- St Leonards
- New South Wales
Healius Limited provides facilities and support services to independent general practitioners, radiologists, and other healthcare professionals in Australia. The company operates through three segments: Pa...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/09/18 08:03|
|End of Day Share Price||2021/09/17 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.